The cost of Alzheimer's disease in China and re-estimation of costs worldwide

IF 13 1区医学 Q1 CLINICAL NEUROLOGY Alzheimer's & Dementia Pub Date : 2018-02-09 DOI:10.1016/j.jalz.2017.12.006

Jianping Jia, Cuibai Wei, Shuoqi Chen, Fangyu Li, Yi Tang, Wei Qin, Lina Zhao, Hongmei Jin, Hui Xu, Fen Wang, Aihong Zhou, Xiumei Zuo, Liyong Wu, Ying Han, Yue Han, Liyuan Huang, Qi Wang, Dan Li, Changbiao Chu, Lu Shi, Min Gong, Yifeng Du, Jiewen Zhang, Junjian Zhang, Chunkui Zhou, Jihui Lv, Yang Lv, Haiqun Xie, Yong Ji, Fang Li, Enyan Yu, Benyan Luo, Yanjiang Wang, Shanshan Yang, Qiumin Qu, Qihao Guo, Furu Liang, Jintao Zhang, Lan Tan, Lu Shen, Kunnan Zhang, Jinbiao Zhang, Dantao Peng, Muni Tang, Peiyuan Lv, Boyan Fang, Lan Chu, Longfei Jia, Serge Gauthier

{"title":"The cost of Alzheimer's disease in China and re-estimation of costs worldwide","authors":"Jianping Jia, Cuibai Wei, Shuoqi Chen, Fangyu Li, Yi Tang, Wei Qin, Lina Zhao, Hongmei Jin, Hui Xu, Fen Wang, Aihong Zhou, Xiumei Zuo, Liyong Wu, Ying Han, Yue Han, Liyuan Huang, Qi Wang, Dan Li, Changbiao Chu, Lu Shi, Min Gong, Yifeng Du, Jiewen Zhang, Junjian Zhang, Chunkui Zhou, Jihui Lv, Yang Lv, Haiqun Xie, Yong Ji, Fang Li, Enyan Yu, Benyan Luo, Yanjiang Wang, Shanshan Yang, Qiumin Qu, Qihao Guo, Furu Liang, Jintao Zhang, Lan Tan, Lu Shen, Kunnan Zhang, Jinbiao Zhang, Dantao Peng, Muni Tang, Peiyuan Lv, Boyan Fang, Lan Chu, Longfei Jia, Serge Gauthier","doi":"10.1016/j.jalz.2017.12.006","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The socioeconomic costs of Alzheimer's disease (AD) in China and its impact on global economic burden remain uncertain.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We collected data from 3098 patients with AD in 81 representative centers across China and estimated AD costs for individual patient and total patients in China in 2015. Based on this data, we re-estimated the worldwide costs of AD.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The annual socioeconomic cost per patient was US $19,144.36, and total costs were US $167.74 billion in 2015. The annual total costs are predicted to reach US $507.49 billion in 2030 and US $1.89 trillion in 2050. Based on our results, the global estimates of costs for dementia were US $957.56 billion in 2015, and will be US $2.54 trillion in 2030, and US $9.12 trillion in 2050, much more than the predictions by the World Alzheimer Report 2015.</p>\n </section>\n \n <section>\n \n <h3> Discussion</h3>\n \n <p>China bears a heavy burden of AD costs, which greatly change the estimates of AD cost worldwide.</p>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"14 4","pages":"483-491"},"PeriodicalIF":13.0000,"publicationDate":"2018-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jalz.2017.12.006","citationCount":"358","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1016/j.jalz.2017.12.006","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 358

Abstract

Introduction

The socioeconomic costs of Alzheimer's disease (AD) in China and its impact on global economic burden remain uncertain.

Methods

We collected data from 3098 patients with AD in 81 representative centers across China and estimated AD costs for individual patient and total patients in China in 2015. Based on this data, we re-estimated the worldwide costs of AD.

Results

The annual socioeconomic cost per patient was US $19,144.36, and total costs were US $167.74 billion in 2015. The annual total costs are predicted to reach US $507.49 billion in 2030 and US $1.89 trillion in 2050. Based on our results, the global estimates of costs for dementia were US $957.56 billion in 2015, and will be US $2.54 trillion in 2030, and US $9.12 trillion in 2050, much more than the predictions by the World Alzheimer Report 2015.

Discussion

China bears a heavy burden of AD costs, which greatly change the estimates of AD cost worldwide.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

中国阿尔茨海默病的成本和全球成本的重新估计

中国阿尔茨海默病(AD)的社会经济成本及其对全球经济负担的影响仍不确定。我们收集了来自中国81个代表性中心的3098例AD患者的数据，并估计了2015年中国个体患者和总患者的AD成本。基于这些数据，我们重新估算了全球范围内的广告成本。结果2015年每位患者的年度社会经济成本为19144.36美元，总成本为1677.4亿美元。预计到2030年，年度总成本将达到5074.9亿美元，到2050年将达到1.89万亿美元。根据我们的研究结果，2015年全球痴呆症费用估计数为9575.6亿美元，2030年将达到2.54万亿美元，2050年将达到9.12万亿美元，远高于《2015年世界阿尔茨海默病报告》的预测。中国承担着沉重的AD成本负担，这极大地改变了全球AD成本的估计。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.